H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Genocea Biosciences (NASDAQ: GNCA) today and set a price target of $5. The company’s shares opened today at $0.94, close to its 52-week low of $0.79.
Pantginis observed:
“GEN-009 IND Filed; The Drive Towards Initial Data Begins Clinical validation of GEN-009 may provide a new therapeutic tool to boost anti-tumor immunity in cancer patients at risk of relapse. This morning, Genocea announced the filing of an Investigational New Drug (IND) application with the FDA for GEN-009, the company’s lead personalized neoantigen anti-cancer vaccine candidate. The Phase 1/2a clinical program is expected to examine the safety, immunogenicity, and eventually clinical efficacy of GEN-009 in cancer patients. The program, which is slated to start later this year, is expected to release first data readout in 1H19. From a clinical standpoint, the program is projecting the enrollment of six patients across various solid tumor types including melanoma, non-small cell lung cancer, head and neck cancer and urothelial carcinoma.”
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -14.5% and a 32.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Genocea Biosciences is Strong Buy and the average price target is $3.75, representing a 298.9% upside.
In a report issued on April 18, Cantor Fitzgerald also maintained a Buy rating on the stock with a $5 price target.
See today’s analyst top recommended stocks >>
Based on Genocea Biosciences’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $0 and GAAP net loss of $10.73 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $13.74 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genocea Biosciences engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses.
Read More on GNCA:
A New Bull Sees 385% Upside for Genocea Biosciences Inc (NASDAQ:GNCA)
Genocea Biosciences Inc (GNCA) Shares Gain 17% in After Hours Trading – Here’s Why
